Overview

Ulcerative colitis is a type of inflammatory bowel disease affecting millions of people globally, causing chronic inflammation of the rectum and colon. Symptoms can include rectal bleeding, persistent diarrhoea, urgency, and abdominal pain, which can significantly reduce patients’ quality of life. In severe or treatment-resistant UC patients, the final resort is surgery. The gold standard surgery solution is known as a proctocolectomy alongside ileal pouch anal anastomosis (IPAA).¹ This procedure removes the colon and rectum, and uses the small intestine to create a small pouch to restore bowel function. Although IPAA is an effective surgical intervention by removing the affected colon and reducing the chances of a permanent stoma, it comes with its difficulties: pouchitis.

Pouchitis is an inflammatory disease that targets the newly created pouch with symptoms similar to UC flairs.² The connection between UC and pouchitis is strong, as pouchitis exclusively occurs in UC patients, indicating a hidden root connection between the two conditions.

The following article will delve into the hidden connection between pouchitis and UC, exploring shared pathogenesis, risk factors, and treatment difficulties, while discussing emerging therapies that will offer relief for patients suffering from these chronic diseases.

Ulcerative colitis: symptoms, diagnosis and surgical treatment

UC is a chronic inflammatory condition of the colon, initiated by an imbalance in the immune response to gut microbiota in genetically predisposed individuals. The mucosal layer is the main layer in which inflammation is confined.³ Inflammation typically starts within the rectum and continuously spreads throughout the colon. The majority of patients will often experience chronic diarrhoea with mucus and blood, tenesmus and abdominal pain, impacting patients’ quality of life significantly.

Diagnosis of UC involves:

• Histopathology: analysing chronic inflammatory changes within cells of the gut
• Colonoscopy: utilising a camera to visualise the mucosal layer and any ulcerations
• Biomarkers: blood tests can reveal high levels of C-reactive protein, which can indicate inflammation. Stool tests can detect levels of calprotectin, which can suggest inflammation within the rectum and the colon⁴

In severe cases of UC, surgery may be required when alternative treatment methods have not worked. The ileal pouch-anal anastomosis is the gold standard procedure which may be better suited to patients in comparison to the permanent stoma. This procedure includes three stages:

• Proctocolectomy: this is where the colon and rectum are removed
• Creating a new ileal pouch: the small intestine is then reshaped into a W, S or J-shaped pouch, which acts as a stool reservoir
• Anastomosis to the anus: the pouch is then connected to the anus to preserve continence

Although IPAA may be an effective treatment for UC patients, it can come with its own risk: pouchitis. This complication can affect 40-60% of UC patients within 10 years post-operation, which highlights a complex connection between pouchitis and UC.⁵

Pouchitis: definition, symptoms and risk factors

Pouchitis is the inflammation of the ileal pouch, majorly presenting in patients with severe UC who have had to undergo (IPAA) surgery. It can present similarly to UC flare-ups and is the most common long-term complication following surgery, with nearly 50% of patients developing pouchitis. Symptoms of pouchitis include watery stools, rectal bleeding, urgency, abdominal cramps, and fatigue. 

Pouchitis is not as common in individuals with familial adenomatous polyposis (FAP) who also undergo the same surgery.⁶ This finding indicates that the underlying pathology of UC makes patients susceptible to pouchitis. Multiple risk factors can increase the probability of pouchitis, including:

• Duration and severity of UC: patients who exceed significant levels of inflammation possess a higher risk of developing pouchitis
• Disease duration - patients with prolonged UC have an increased likelihood of pouchitis following surgery
• Dysbiosis of the gut: imbalances in gut microbiota can trigger pro-inflammatory reactions, which is common in UC patients
• Extensive NSAID usage: Non-steroidal anti-inflammatory drugs (NSAIDs) can induce a positive feedback reaction and cause further inflammation of the pouch⁷

These combined risk factors demonstrate the inflammatory connection between pouchitis and UC, making it a consistent challenge for post-op patients. 

The link between UC and pouchitis pathophysiology: A combined inflammatory battle

The connection between UC and pouchitis stems from their similar inflammatory pathways, dysbiosis of the gut, and immune dysregulation. Within both conditions, the immune system produces an abnormal response to antigens in the gut, which can trigger chronic inflammation. In UC, this inflammatory attack primarily targets the mucosa of the colon; whereas in pouchitis, the ileal pouch is susceptible to the same inflammatory cascade. The process is driven through pro-inflammatory cytokines such as interleukin-6 (IL-6) and interleukin-23 (IL-23),⁸ which can cause chronic tissue damage. 

Dysbiosis of the gut can further exacerbate the inflammatory cycle. Pouchitis and UC patients possess a significant reduction in essential gut bacteria such as Faecalibacterium and Bifidobacterium,⁹ which aid in maintaining homeostasis within the gut. Simultaneously, there is an overgrowth of pathogenic bacteria, such as Enterococcus faecalis and Escherichia coli, which induce inflammation and increase disease severity.¹⁰

Vulnerability is increased via genetic susceptibility, with unique genes linked to both pouchitis and UC. Gene mutations within ATG16L1, IL23R, and NOD2,¹¹ which play a role in autophagy and immune regulation, can lead to increased inflammation and weaken the protective barrier of the gut, which increases the chance of UC patients developing pouchitis. The combination of microbial imbalance, genetic predisposition and imbalanced immune response displays why pouchitis is not just a complication post-surgery but rather is the continued prognosis of UC.

Diagnostic challenges in differentiating pouchitis from UC

Diagnosis of pouchitis in UC patients can be very difficult due to their shared symptoms and similar inflammatory responses. Both conditions present with abdominal cramping, rectal bleeding, and diarrhoea, making clinical differentiation challenging. Endoscopy findings in pouchitis and UC both display ulcerations, mucosal inflammation, and erythema; histologically, the two conditions are astonishingly similar, displaying atrophy, abscesses, and neutrophil infiltration, making it even more challenging to distinguish between them.

Accurate diagnosis of pouchitis is essential to distinguish it from other disorders which present with similar clinical symptoms. Cuffitis is when the rectal cuff of the remaining ileal pouch gets inflamed which can present similar symptoms such as urgency and rectal bleeding. Crohn's disease of the pouch can develop after IPAA surgery. It is characterised by strictures, fistula production, and transmural inflammation,¹² which distinguishes it from pouchitis. Early and accurate diagnosis of pouchitis is vital to prevent mismanagement and ensure the delivery of appropriate treatment.

Treatment for pouchitis and UC: fighting inflammation head-on

Despite UC and pouchitis being distinct conditions, their similar inflammatory pathology suggests they can respond to overlapping treatment. The primary treatment of pouchitis includes antibiotics, with metronidazole and ciprofloxacin commonly used to eliminate inflammation and suppress symptoms.¹³ Persistent or recurrent pouchitis may require strong probiotics such as VSL 3, which can repair the gut microbiome balance and maintain remission. Refractory pouchitis can be treated with biological therapies such as anti-TNF agents (like vedolizumab and infliximab), which offer significant inflammation suppression.¹⁴

UC treatment also focuses on reducing inflammation and preventing flare-ups. Corticosteroids and 5-aminosalicylic acids (5-ASAs) are the gold standard therapies for mild or moderate UC. In severe cases, biological agents such as immunomodulators may also be considered. The similar treatment strategies highlight the shared inflammatory pathway of these two conditions.

Future directions: making new boundaries of treatment

Ongoing and future research into novel therapies is creating more effective treatment strategies for pouchitis and UC. An exciting new approach is faecal microbiota transplantation (FMT),¹⁵ which involves taking healthy gut bacteria from a healthy donor into the patient's intestine. By restoring microbial balance, this approach aids in decreasing inflammation and inducing long-term remission, especially in patients with recurrent or chronic pouchitis. Furthermore, IL-23 inhibitors, including risankizumab, are being clinically tested as a potential targeted therapy for recurrent pouchitis. Blocking the mechanism in which these pro-inflammatory cytokines work gives the potential for these therapies to significantly improve long-term outcomes in patients who do not respond to conventional treatments. As research is ongoing, these future therapies may offer hope for the unique and effective management of these conditions.

Conclusion

The strong link between pouchitis and UC is driven by shared immune dysregulation, genetic factors, and microbial imbalances. UC patients have been given significant life-changing relief through (IPPA) surgery by removing the affected colon; however, it comes with the chance of developing pouchitis, a complication which involves inflammation of the newly created pouch and closely resembles flare-ups of UC. This hidden connection indicates how the underlying inflammation of UC can persist post-surgery. Management of pouchitis primarily includes antibiotics and corticosteroids; however, ongoing research has displayed new therapies, such as IL-23 inhibitors and FMT, which can improve the quality of life. Nonetheless, management is usually lifelong and requires advanced treatments to suppress inflammation and achieve remission, accentuating the lasting complex nature of UC.